☆ 4.5 Article

Lurasidone Augmentation of Clozapine in Schizophrenia—Retrospective Chart Review

Brain Sciences (2023)

Related references

Note: Only part of the references are listed.

Review Psychiatry

Pharmacological and nonpharmacological augmentation treatments for clozapine-resistant schizophrenia: A systematic review and network meta-analysis with normalized entropy assessment

Ta-Chuan Yeh et al.

Summary: The objective of this study was to integrate evidence from randomized controlled trials (RCTs) to compare the efficacy of pharmacological and nonpharmacological augmentation interventions for clozapine-resistant schizophrenia. A systematic search of six major electronic databases was conducted, and the primary outcome measure was the change in overall symptoms. Network meta-analysis was performed using random-effects models, and the uncertainty of treatment ranking was assessed using normalized entropy.

ASIAN JOURNAL OF PSYCHIATRY (2023)

Add to Collection

Review Pharmacology & Pharmacy

Clozapine augmentation with cariprazine for negative symptoms: a case series and literature review

Ebenezer Oloyede et al.

Summary: Cariprazine combined with clozapine has been shown to be clinically effective in treating negative symptoms in patients with treatment-resistant psychosis. Cariprazine is a novel antipsychotic drug with partial agonism at dopamine D-2 and D-3 receptors, antagonism of 5HT(2B) receptors, and partial agonism at 5HT(1A) receptors.

THERAPEUTIC ADVANCES IN PSYCHOPHARMACOLOGY (2022)

Add to Collection

Article Neurosciences

Add-on Cariprazine in Patients with Long-term Clozapine Treatment and Treatment Resistant Schizophrenia: Two Cases of Psychotic Deterioration and Pisa Syndrome

Judith Weise et al.

Summary: An increasing number of studies are focusing on medical options for treatment resistant schizophrenia. When clozapine fails to achieve remission, a combination of antipsychotics can be considered. The combination of clozapine and cariprazine, a dopamine D2 and D3 receptor partial agonist, is rarely studied despite its pharmaceutical rationality. Two patients with long-term treatment resistant schizophrenia who received both cariprazine and clozapine experienced worsened psychotic symptoms and extrapyramidal side effects, specifically Pisa syndrome. The syndrome improved after discontinuing cariprazine. Possible explanations are discussed, involving pharmacodynamic interactions and drug-specific receptor profiles.

CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE (2022)

Add to Collection

Review Psychiatry

Clozapine resistant schizophrenia: Newer avenues of management

Subho Chakrabarti

Summary: Research has shown that the current augmentation strategies for treatment-resistant schizophrenia with clozapine are often ineffective, prompting the need for newer treatment approaches. It may be beneficial to develop clinical consensus on effective augmentation strategies and use them sequentially in patients with CRS, as well as consider alternatives such as augmentation with long-acting antipsychotic injections or multi-component psychosocial interventions. Efforts to optimize clozapine treatment, including personalized dosing and addressing clinician barriers, may also be key in managing CRS until further research provides clearer directions for augmenting clozapine response.

WORLD JOURNAL OF PSYCHIATRY (2021)

Add to Collection

Article Neurosciences

Cariprazine Add-on in Inadequate Clozapine Response: A Report on Two Cases

Domenico De Berardis et al.

Summary: Cariprazine is a novel antipsychotic drug that has shown clinical efficacy in treating schizophrenia, bipolar disorder, and Major Depressive Disorder. It can also be used as an adjunctive treatment in drug-resistant MDD patients. Combination therapy with cariprazine has shown benefits for patients with treatment-resistant schizophrenia, even improving adverse metabolic effects of other medications like clozapine.

CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE (2021)

Add to Collection

Review Chemistry, Medicinal

Withdrawal Symptoms Following Discontinuation of Vortioxetine-Retrospective Chart Review

Marcin Siwek et al.

Summary: The study found that around 3% of patients who discontinued vortioxetine treatment experienced discontinuation symptoms, including emotional lability, irritability, and sudden worsening of mood. These symptoms typically appeared three days after withdrawal and lasted for approximately seven days.

PHARMACEUTICALS (2021)

Add to Collection

Article Neurosciences

Lurasidone in Therapy of Treatment-resistant Ultra-rapid Cycling Bipolar Disorder: Case Report

Marcin Siwek et al.

Summary: This case study demonstrates the efficacy of lurasidone in treating treatment-resistant ultra-rapid cycling bipolar disorder in a 25-year-old female patient. Clinical improvement was observed after 3 weeks of treatment, with cessation of the ultra-rapid cycling course of the disease after 8 weeks. The patient's functioning improved and body mass significantly decreased with good tolerance of the medication.

CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE (2021)

Add to Collection

Article Pharmacology & Pharmacy

Lurasidone Improves Psychopathology and Cognition in Treatment-Resistant Schizophrenia

Herbert Y. Meltzer et al.

JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY (2020)

Add to Collection

Review Neurosciences

Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives

Frederick C. Nucifora et al.

NEUROBIOLOGY OF DISEASE (2019)

Add to Collection

Review Clinical Neurology

Clozapine augmentation strategies - a systematic meta-review of available evidence. Treatment options for clozapine resistance

Elias Wagner et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2019)

Add to Collection

Review Psychiatry

Treatment resistant schizophrenia - review and a call to action

J. Lally et al.

IRISH JOURNAL OF PSYCHOLOGICAL MEDICINE (2019)

Add to Collection

Article Clinical Neurology

Dopamine D4 receptor stimulation contributes to novel object recognition: Relevance to cognitive impairment in schizophrenia

Masanori Miyauchi et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2017)

Add to Collection

Review Psychiatry

Clozapine Response Rates among People with Treatment-Resistant Schizophrenia: Data from a Systematic Review and Meta-Analysis

Dan Siskind et al.

CANADIAN JOURNAL OF PSYCHIATRY-REVUE CANADIENNE DE PSYCHIATRIE (2017)

Add to Collection

Review Psychiatry

Clozapine V. first-and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis

Dan Siskind et al.

BRITISH JOURNAL OF PSYCHIATRY (2016)

Add to Collection

Article Gastroenterology & Hepatology

Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease

Sara Heeboll et al.

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY (2016)

Add to Collection

Review Psychiatry

Schizophrenia: when clozapine fails

Seiya Miyamoto et al.

CURRENT OPINION IN PSYCHIATRY (2015)

Add to Collection

Article Psychiatry

Efficacy of lurasidone across five symptom dimensions of schizophrenia: Pooled analysis of short-term, placebo-controlled studies

A. Loebel et al.

EUROPEAN PSYCHIATRY (2015)

Add to Collection

Article Clinical Neurology

Treatment resistant or resistant to treatment? Antipsychotic plasma levels in patients with poorly controlled psychotic symptoms

Robert McCutcheon et al.

JOURNAL OF PSYCHOPHARMACOLOGY (2015)

Add to Collection

Article Psychiatry

Effect of lurasidone dose on cognition in patients with schizophrenia: Post-hoc analysis of a long-term, double-blind continuation study

Philip D. Harvey et al.

SCHIZOPHRENIA RESEARCH (2015)

Add to Collection

Article Clinical Neurology

Psychosocial functioning in schizophrenia: are some symptoms or demographic characteristics predictors across the functioning domains?

Sirijit Suttajit et al.

NEUROPSYCHIATRIC DISEASE AND TREATMENT (2015)

Add to Collection

Article Pharmacology & Pharmacy

Clinical predictors of serum clozapine levels in patients with treatment-resistant schizophrenia

Anto P. Rajkumar et al.

INTERNATIONAL CLINICAL PSYCHOPHARMACOLOGY (2013)

Add to Collection

Article Psychiatry

Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial

Antony Loebel et al.

SCHIZOPHRENIA RESEARCH (2013)

Add to Collection

Article Psychiatry

Augmentation of clozapine with a second antipsychotic - a meta-analysis

D. M. Taylor et al.

ACTA PSYCHIATRICA SCANDINAVICA (2012)

Add to Collection

Review Clinical Neurology

Critical appraisal of lurasidone in the management of schizophrenia

Silvio Caccia et al.

NEUROPSYCHIATRIC DISEASE AND TREATMENT (2012)

Add to Collection

Article Psychiatry

Lurasidone in the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo- and Olanzapine-Controlled Study

Herbert Y. Meltzer et al.

AMERICAN JOURNAL OF PSYCHIATRY (2011)

Add to Collection

Article Pharmacology & Pharmacy

Pharmacological Profile of Lurasidone, a Novel Antipsychotic Agent with Potent 5-Hydroxytryptamine 7 (5-HT7) and 5-HT1A Receptor Activity

Tadashi Ishibashi et al.

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)

Add to Collection

Article Psychology, Clinical

Lurasidone in the Treatment of Acute Schizophrenia: A Double-Blind, Placebo-Controlled Trial

Mitsutaka Nakamura et al.

JOURNAL OF CLINICAL PSYCHIATRY (2009)

Add to Collection

Review Psychiatry

Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: A review and meta-analysis of randomized trials

M Chakos et al.

AMERICAN JOURNAL OF PSYCHIATRY (2001)

Add to Collection

© Peeref 2019-2024. All rights reserved.